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Positive  controls  are  an  important  component  of  the  quality-control  of  molecular  tests  used  for  diagnosis
of  livestock  diseases.  For  high  consequence  agents  such  as  foot-and-mouth  disease  virus  (FMDV),  the
positive  controls  required  to monitor  template  extraction,  reverse  transcription  and  ampliﬁcation  steps
usually  consist  of  material  derived  from  infectious  viruses.  Therefore,  their  production  is dependent  upon
the use  of high  containment  facilities  and  their  deployment  carries  the  risks  associated  with  inactivation
of  “live”  FMDV.  This  paper  describes  the  development  of  a novel  non-infectious  positive  control  that
encodes  FMDV  RNA  sequences  that are  encapsidated  within  Cowpea  mosaic  virus  (CPMV)  particles.  This
surrogate  RNA  has  been  engineered  to contain  sequences  from  the  5′UTR and  3D  regions  of FMDV  targeted
by  many  molecular  assays  (conventional  RT-PCR,  real-time  RT-PCR  and  RT-LAMP).  These sequences  were
inserted  into  a movement-deﬁcient  version  of CPMV  RNA-2  which  is  rescued  from  cowpea  plants  (Vigna
unguiculota)  by inoculation  with  RNA-1.  In order  to evaluate  the  performance  of  these  encapsidated  RNAs,
nucleic  acid  prepared  from  a  10-fold  dilution  series  was  tested  using  a  range  of  molecular  assays.  Results
generated  by  using  the  molecular  assays  conﬁrmed  RNA-dependent  ampliﬁcation  and  the  suitability  of
these  particles  for use  in  a range  of  diagnostic  tests.  Moreover,  these  CPMV  particles  were  highly  stable
for  periods  of up  to  46 days  at room  temperature  and  37 ◦C.  Recombinant  CPMV  can  be used  to  produce
high  yields  of  encapsidated  RNAs  that can  be used  as  positive  and  negative  controls  and  standards  in
molecular  assays.  This approach  provides  a  surrogate  that can  be  potentially  used  outside  of  containment
laboratories  as  an  alternative  to inactivated  infectious  virus  for  molecular  diagnostic  testing.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
Early detection is key for the control and eventual eradication
f many viral diseases. Real-time Reverse Transcription PCR (RT-
PCR) is widely used as a routine diagnostic tool for livestock
iseases such as foot-and-mouth disease (FMD; Hoffmann et al.,
009). Nevertheless, the performance of these molecular proto-
ols can be impacted by human errors and the shelf-life of the
nzymes used for template ampliﬁcation. Therefore, processing a
urrogate template as a positive control in parallel with clinical
amples is a necessary component of validation to rule out false
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negative results. These positive controls usually consist of material
derived from infectious viruses, which for high-impact livestock
diseases such as FMD  are dependent upon the use of high con-
tainment facilities and associated bio-safety risks. An alternative
strategy, utilises internal controls produced via in vitro transcrip-
tion (Heath et al., 2003; Westcott et al., 2003), and studies have
indicated that in vitro transcribed RNA can be stored at −20 ◦C and
undergo 40 cycles of freeze–thawing, or stored at 37 ◦C for 12 days
with no negative inﬂuence on the subsequent RT-PCR ampliﬁcation
(Hoffmann et al., 2006). However, without special precautions or
buffer conditions, these synthetic RNA internal controls are rela-
tively unstable and can easily be degraded by cellular enzymes. In
view of these disadvantages, this paper describes the development
of a novel non-infectious encapsidated viral RNA that can be used
as a positive control in molecular diagnostic tests.
Cowpea mosaic virus (CPMV) is a plant virus which belongs
to the Comoviridae family within the new order Picornavirales.  Its
genome consists of two  molecules of positive sense RNA that are
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ncapsidated separately in very stable icosahedral virus particles
hich can survive at 60 ◦C for an hour across a pH range 4–9
Montague et al., 2011). While RNA-1 is about 6.0 kb in length,
NA-2 is about 3.5 kb, permitting additional lengths of sequence
o be inserted into RNA-2 without abolishing its ability to be repli-
ated and packaged in plants (Gopinath et al., 2000; Monger et al.,
006). CPMV shares similarities in terms of genome organisa-
ion and capsid structure with Picornaviruses such as FMD  virus
FMDV) and swine vesicular disease virus (SVDV). CPMV is a good
andidate to provide recombinant viral particles containing het-
rologous sequences since it can be puriﬁed easily and at high
ield from infected plants with up to 1 mg  of particles per gram
f infected leaf tissue (Montague et al., 2011). The possibility of
nserting an untranslated FMDV sequence downstream of CPMV
NA-2 sequence encoding the small (S) protein has been pre-
iously demonstrated (King et al., 2007). Although the resulting
irus particles served as efﬁcient real-time RT-PCR controls, the
pproach suffered from two disadvantages: the creation of the
ontrol constructs was a multistep process and the particles pro-
uced retained their ability to give a productive infection in plants.
hough the latter problem could be reduced by physically sepa-
ating the RNA-2-containing particles in a preparation (King et al.,
007), this is a time-consuming and often incomplete process. This
aper describes the design of a construct that produces recom-
inant CPMV particles that are incapable of causing a productive
nfection on plants and into which heterologous sequences can be
nserted in a single step. The particles are shown to form the basis
f a highly effective and safe positive control for the molecular
ectection of FMDV.
ig. 1. A cartoon outlining the cloning strategy used to create an engineered FMDV surro
lasmids are indicated and the location of Cauliﬂower mosaic virus 35S promoter (35S)
MP  del), large coat protein (L), small coat protein (S), 3′ end of CPMV RNA-2 (3′) and th
onstruct (FMDV) is shown in pBIN-mim-AvrII-mp del FMDV.l Methods 220 (2015) 27–34
2. Materials and methods
2.1. Strategy used to produce movement-deﬁcient Cowpea
mosaic virus (CPMV)
To facilitate one-step cloning of a heterologous sequence into
a full-length copy of RNA-2 of CPMV, an ApaI restriction enzyme
(RE) digestion site was  introduced between the PstI and StuI RE
sites in the 3′UTR of plasmid pCVW (Gopinath et al., 2000). The 2 kb
BamHI-EcoRI fragment from pCVW ApaI encompassing the 3′ end
of RNA-2 was  then ligated into a similarly digested fragment from
the plasmid pBinP-NS-ER-DsRed (Sainsbury et al., 2008) to create
the binary plasmid pBin-mim. An oligonucleotide containing the
sequence of an AvrII site was  then inserted into the unique ApaI site
of pBin-mim to create pBIN-mim-AvrII (Fig. 1). This plasmid allows
any sequence with ApaI and AvrII-compatible ends to be cloned
downstream of the open reading frame of an infectious clone of
CPMV RNA-2 in a single step. To create a movement-deﬁcient ver-
sion of CPMV, plasmid pN81S2NT, containing a full-length copy of
CPMV RNA-2 (Liu and Lomonosoff, 2002) was  digested with NdeI
and AccI. Following treatment with Escherichia coli DNA polymerase
I (Klenow fragment) to remove overhangs, the RNA was  re-ligated
to give plasmid pN81mp del in which a 456 nucleotide section
from the 48K movement protein sequence had been removed while
retaining the open reading frame of the polyprotein. Restriction
enzyme digestion of pN81mp del with PacI and BamHI released
a fragment carrying the deleted version of the movement pro-
tein; this was substituted for the equivalent wild-type sequence
in pBin-mim-AvrII to give plasmid pBIN-mim-AvrII-mp del (Fig. 1).
gate RNA within a movement deﬁcient CPMV particle. The identity of the different
, as well as regions encoding CPMV movement protein (MP), partially deleted MP
e Agrobacterium nopaline synthase terminator (nos). The location of the artiﬁcial
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Fig. 2. Complete sequence of the engineered FMDV surrogate RNA showing locations of the different regions of the FMDV genome: 3D conventional RT-PCR targets (3D:
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D  encoding region encompassing the molecular targets for a number of diagnostic
nd  incorporates point nucleotide substitutions (*) to reduce the mismatch of the e
his plasmid allows direct insertion of ApaI-AvrII sequences into a
ovement-deﬁcient version of RNA-2 (Fig. 1).
.2. Design of artiﬁcial construct containing primer sites for
MDV diagnostic assays
A 512 bp nucleic acid sequence was designed to contain the
olecular targets for two conventional (agarose gel-based) RT-
CRs, two RT-qPCR and two RT-LAMP assays used to detect FMDV
Fig. 2). This fragment embodies forward and reverse primer sites
shown in Table 1), short ﬂanking regions and probe sites for these
reviously published FMDV assays. Nucleotides at positions 869,
019, and 8028 of FMDV O1 Manisa (GenBank accession num-
er AY593823) were substituted from A to C, C to T, and T to C,
espectively, to reduce the nucleotide mismatch of the engineered
onstruct with the primer and probe sequences used in the FMDV
iagnostic assay. Thus, the FMDV surrogate RNA sequence with
dded ApaI and AvrII ﬂanking sites was synthesised by GeneArt
Life Technologies). Following digestion with ApaI and AvrII, the
equence was inserted into similarly digested plasmid pBIN-mim-
vrII-mp del to yield pBIN-mim-AvrII-mp del-FMDV (Fig. 1). The
ransformation of plasmids into Agrobacterium tumefaciens strain
BA4404, the inﬁltration of cowpea (Vigna unguiculata) plants andUTR encompassing a real-time RT-PCR assay (5′UTR: grey boxes) and a part of the
 (3D: open box). This sequences is based on the O1-Manisa FMDV reference isolate
ered construct with the primer and probe sequences used to detect FMDV.
the propagation and puriﬁcation of virus particles was carried out
as described by King et al. (2007).
2.3. Evaluation of the template encapsidated in the CPMV
particles using molecular assays for the detection of FMDV
A sample matrix was ﬁrst prepared by mixing a 10% (w/v) of
negative bovine epithelium (bought from a local abattoir) with M25
phosphate buffered saline (35 mM Na2HPO4; 5.7 mM KH2PO4; pH
7.6) and then ﬁltering the ﬁnal solution. Then, a 10 fold dilution
series was prepared using the recombinant CPMV (at 1 g/l) in
the negative bovine epithelium suspension. This sample matrix
was used since it most closely represented clinical material that
might be received for diagnostic investigation. From each dilution,
viral RNA was extracted (in triplicate) using the QIAmp Viral RNA
Mini kit (Qiagen, UK) with an elution volume of 40 l (according to
manufacturer’s instructions).
2.4. RNA dependent ampliﬁcation using conventional RT-PCRInitial experiments using conventional RT-PCR protocols were
undertaken to conﬁrm that the ampliﬁed template was  RNA, and
that residual DNA from the original plasmid construct did not
30 M. Madi et al. / Journal of Virological Methods 220 (2015) 27–34
Table 1
Sequences of primer recognition sites present in the FMDV positive control.
Primer name Sequence (5′ to 3′) Genomic locationa Position in construct Reference
1F forward GCCTGGTCTTTCCAGGTCT 680–698 21–39 Reid et al.
(2000)1F reverse CCAGTCCCCTTCTCAGATC 1007–989 493–475
IRES  Forward CACYTYAAGRTGACAYTGRTACTGGTAC 898–925 78–105 Reid et al.
(2002)IRES Reverse CAGATYCCRAGTGWCICITGTTA 994–972 156–134
IRES  probe CCTCGGGGTACCTGAAGGGCATCC 971–948 151–128
Rodriguez 3D forward CAGAGATGTGGAAGAGCGCG 6702–6721 1–20
Rodriguez 3D reverse GCGGAACAGCGCTTTGTCC 6909–6891 512–494
Callahan 3D forward ACTGGGTTTTACAAACCTGTGA 7870–7891 250–271 Callahan et al.
(2002)Callahan 3D reverse GCGAGTCCTGCCACGGA 7976–7960 356–340
Callahan 3D probe TCCTTTGCACGCCGTGGGAC 7921–7940 301–320
CHN-F3 TGTGATGGCTTCGAAGACC 7887–7905 267–285 Shao et al.
(2010)CHN-B3 TGCGTCACCGCACACG 8094–8079 474–459
CHN-FIP TGCCACGGAGATCAACTTCTCCTTTTCTCGAGGCTATCCTCTCCTT 7968–7923 348–303
CHN-BIP GAGTACCGGCGTCTCTTTGAGCTTTTCGTTCACCCAACGCAGGTAA 7996–8041 376–421
CHN-LF TGTATGGTCCCACGGCG 7946–7930 326–310
CHN-LB TTGAGCCTTTCCAGGGCC 8012–8029 392–409
UK-F3 CATGGACTATGGAACTGGGT 7857–7876 237–256 Dukes et al.
(2006)UK-B3 GGCCCTGGAAAGGCTCA 8019–8003 409–393
UK-FIP CACGGCGTGCAAAGGAGAGGATTTTACAAACCTGTGATGGCTTCG 7855–7899 235–279
UK-BIP GGAGAAGTTGATCTCCGTGGCATTTTAAGAGACGCCGGTACTCG 7947–7990 327–370
UK-LF TAGCCTCGAGGGTCTTCG 7892–7909 295–278
UK-LB GGACTCGCCGTCCA TCT 7969–7985 267–285
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Oa Primer locations correspond to the complete genome sequence of the FMDV re
nﬂuence the results from the molecular tests. In these experi-
ents, nucleic acid prepared from the dilution series of CPMV was
ivided into two batches; one was subjected to ampliﬁcation by RT-
CR (Reid et al., 2000; Rodriguez et al., 1994), while an experiment
n parallel used identical conditions without the addition of the
T step. The following protocol was used: 5 l of nucleic acid was
dded to 7.5 l nuclease-free water and 0.5 l random hexamers
500 g/ml) (Promega, USA). This mix  was denatured at 65 ◦C for
 min  after which the reaction mix  was held on ice. To this reaction,
 l of a solution containing 4 l of 5× ﬁrst strand buffer (Invitro-
en), 1 l RNase out (40 U/l, Invitrogen), 1 l dNTPs (10 M each)
nd 1 l Superscript III Reverse Transcriptase (200 U/l,  Invitro-
en) was added. RT reaction was performed using the following
rotocol: 50 ◦C for 1 h and 70 ◦C for 15 min. 5 l cDNA sample was
dded to 40 l PCR mix  comprising 5 l of 10X buffer (Invitrogen),
 l MgSO4 (50 mM,  Invitrogen), 1 l dNTPS (10 M each), 1 l
f both 1F forward and 1R reverse primers (10 M),  0.2 l Plat-
num Taq (Invitrogen, UK) and 34.8 l nuclease free water. Both
atches of samples – with or without the RT enzyme in the incuba-
ion step – were ampliﬁed in parallel using the following protocol:
ne cycle of 94 ◦C for 5 min; 40 cycles of 94 ◦C for 1 min, 50 ◦C for
 min, 72 ◦C for 1 min  and one cycle of 72 ◦C for 7 min. Following
his, 10 l of the PCR ampliﬁcation of 10−2 to 10−9 dilution series
as mixed with 2 l loading buffer (Fermentas, Germany). Sam-
les were then loaded in 1% (w/v) agarose and run at 100 V for
0 min.
.5. Detection by diagnostic real-time RT-PCR assays
The template encapsidated in the CPMV particles was evaluated
sing two diagnostic RT-qPCR assays (Reid et al., 2002; Callahan
t al., 2002) using a one-step RT-qPCR protocol previously described
Reid et al., 2009). Brieﬂy, 5 l of 10−2–10−9 dilution RNA samples
repared previously was added to 20 l reaction mix  encompassing
2.5 l of 2× mix  (Invitrogen); 2 l forward primer (10 M);  2 l
everse primer (10 M);  1.5 l probe (5 M);  1.5 l nuclease free
ater and 0.5 l SuperScript III/Taq Polymerase (Invitrogen, UK).
ne step RT-qPCR was performed using the following protocol: onee virus O1 Manisa (GenBank accession number AY593823).
cycle at 60 ◦C for 30 min; one cycle at 95 ◦C for 10 min  and 50 cycles
at 95 ◦C for 15 s and 60 ◦C for 1 min. CT (cycle threshold) values were
assigned as previously described (Reid et al., 2002).
2.6. Detection by LAMP assays
The performance of the template encapsidated in the CPMV
particles was  also evaluated in FMDV-speciﬁc RT-loop-mediated
isothermal ampliﬁcation (RT-LAMP) assays (Dukes et al., 2006;
Shao et al., 2010). In these experiments, 5 l of the 10−2 dilution
RNA sample was  added to 20 l reaction mix  containing 2.5 l of
10× Thermopol buffer (Invitrogen), 1 l of a 50 M stock of internal
primers (IPs: BIP and FIP), 1 l of a 5 M stock of external primers
(EPs: F3 and B3), 1 l of a stock of 25 M of loop primers (Floop
and Bloop), 0.5 l of 10 mM of dNTPs, 0.5 l of 100 mM of MgSO4,
5 l of 5 M of betaine (Sigma Aldrich), 5 l of dye mix, 1.3 l of
nuclease free water, 2 l of 8 U/l  of Bst polymerase (Invitrogen)
and 0.2 l of 15 U/l  of Cloned AMV  RT (Invitrogen) to a ﬁnal vol-
ume  of 25 l. RT-LAMP was carried out on the Mx3005P machine
(Stratagene) under the following conditions: 65 ◦C for 60 min  and
85 ◦C for 5 min. After detection on the Mx3005P machine, ampliﬁed
products were visualised using agarose gel electrophoresis.
2.7. Thermo-stability of the recombinant CPMV particle
Long term stability of CPMV particles was investigated over
a 46 days period. Two  hundred and seventy six aliquots were
prepared using a 10−3 CPMV dilution (∼1 ng/l) sample in 10% neg-
ative bovine epithelium suspension. Aliquots were divided into two
batches; one was stored at room temperature conditions (20–26 ◦C)
while the other was  held at 37 ◦C. After incubation for set of periods
of time, triplicate aliquots were stored in RLT lysis buffer (Qiagen,
Germany) and frozen at −80 ◦C until they were analysed. Once
the experiment was  ﬁnished, nucleic acid was extracted from all
samples using the QIAmp Viral RNA Mini kit (Qiagen, Germany)
according to the manufacturer’s protocol with 40 l elution vol-
ume. Then, 5 l RNA sample was  added to 20 l RT-qPCR master
M. Madi et al. / Journal of Virological Methods 220 (2015) 27–34 31
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Fig. 4. Conventional PCR detection of the FMDV surrogate RNA template with (A) or
without (B) reverse transcription step. Figure shows an agarose-gel visualisation of
−2 −3 −4 −5 −6
materials for proﬁciency testing schemes (Ferris et al., 2006), partic-ig. 3. Recombinant Cowpea Mosaic Virus particle containing surrogate FMDV RNA
equences visualised by electron microscope.
ix  as described above and a one step RT-qPCR reaction targeting
he FMDV 3D region was performed.
. Results
.1. Production of CPMV particles based on movement deﬁcient
irus
Agroinﬁltration of ten cowpea plants with pBIN-mim-AvrII-
p del or pBIN-mim-AvrII-mp del-FMDV, containing the deleted
ersion of the 48K movement protein, did not result in disease
ssociated symptoms appearing on the upper leaves, suggesting
hat any infection was restricted to the area which was inﬁltrated.
ap extracted from the inoculated tissue was unable to initiate
n infection on healthy cowpeas; by contrast sap extracted from
eaves of ﬁve cowpea plants inﬁltrated with constructs with an
ntact 48K protein gave 100% infection when passaged to healthy
lants. These results conﬁrmed that the deletion within the 48K
rotein had effectively abolished the infectivity of the virus. Puriﬁ-
ation of particles from inﬁltrated tissue gave yields of 3–4 mg  per
g wet weight leaf tissue, approximately 1% of the yield obtained
ith wild-type virus. This is consistent with the inability of the
irus to move out of the initially infected cells. Transmission elec-
ron microscopy revealed that the preparations contained particles
ndistinguishable from wild-type CPMV (Fig. 3).
.2. RNA dependent ampliﬁcation of the template encapsidated
ithin the CPMV particles
The nature of the template contained in the engineered CPMV
ositive controls was tested using nucleic acid extracted from a
ilution series of the CPMV particles. Dilutions (10−2 to 10−5:
ells 1–4 of Fig. 4A) which were subjected to a RT step prior
o PCR ampliﬁcation generated an expected ampliﬁcation band
round 435 bp on the agarose gel. However, parallel samples
hich were only ampliﬁed by PCR without a RT step displayed
o ampliﬁcation bands (wells 1–4 of Fig. 4B). Moreover, nucleic
cid extracted from negative bovine suspension sample failed to
xhibit an ampliﬁcation signal on the agarose gel in either con-
ition (well 9 of Fig. 4A and B). These results conﬁrmed that thethe  Log dilutions of CPMV particles 10 (−2); 10 (−3); 10 (−4); 10 (−5) 10
(−6), 10−7 (−7) 10−8 (−8) 10−9 (−9) and negative bovine epithelium suspension
(Neg) using PCR primers (1F/1R) that target the 5′UTR of the FMDV genome.
positive signal generated from the recombinant CPMV particles was
RNA-dependent.
3.3. Detection of the template encapsidated in the CPMV particles
using previously published diagnostics assays
A decimal titration series from 10−2 to 10−9 prepared with
recombinant CPMV particles in 10% negative bovine epithelium
suspension has been tested for previously published diagnostic
assays. Results conﬁrmed the ability of the nucleic acid extracted
from the dilution series to be positively ampliﬁed using the FMDV
RT-qPCR 3D assay (Fig. 5). Similar results were generated using RT-
qPCR targeting the FMDV 5′UTR region (results not shown). One
representative sample from the dilution series was used to test
two RT-LAMP assays (Dukes et al., 2006 and Shao et al., 2010).
Fig. 6A demonstrates positive ampliﬁcation with RNA at around
40 min  and 43 min  for the Dukes et al. (2006), and Shao et al.
(2010), RT-LAMP assays, respectively. Nucleic acid extracted from
negative bovine controls failed to generate a positive curve using
either RT-LAMP assays. These results generated using a real-time
PCR machine were conﬁrmed using agarose gel electrophoresis
which revealed laddering patterns characteristic of post ampliﬁ-
cation LAMP products (Fig. 6B).
3.4. Thermo-stability of the recombinant CPMV particles
Long term thermo-stability of recombinant CPMV particles has
been monitored over a period of 46 days. All RNA samples extracted
from the recombinant CPMV particles previously stored at room
temperature (20–25 ◦C) or stored at 37 ◦C generated positive ampli-
ﬁcation throughout the 46 days period, displaying CT values ranging
from 23 to 27 (Fig. 7).
4. Discussion
FMD  is a highly infectious disease of both domestic and
wild cloven-hoofed animals. FMDV (Family: Picornaviridae,
genus: Aphthovirus), the causative agent is normally handled in
high-containment laboratories that employ robust bio-security
measures to prevent exposure to susceptible animals. Conventional
approaches used to prepare positive controls and standard mate-
rials that can be shipped between laboratories rely on the use of
inactivated material containing infectious FMDV. The use of theseularly in those laboratories that work at lower containment levels
requires that validated inactivation approaches are used. However,
the chemical (BEI) treatment to inactivate the live virus requires
32 M. Madi et al. / Journal of Virological Methods 220 (2015) 27–34
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sig. 5. Detection of FMDV surrogate viral RNA in the recombinant CPMV particle u
eterminations of a 10-fold dilution series of the CPMV particle (starting at 1 g/l
ery expensive and time consuming in vitro and in vivo testing in
rder to verify the non-infectivity of the ﬁnal product.
In this study, a surrogate FMDV RNA was engineered and encap-
idated into a CPMV particle. This RNA contains a 512 nucleotide
NA fragment comprising the sequence targets for six pan-serotype
ssays used for routine diagnostics of FMD: two RT-qPCRs, targeting
ither the 5′UTR (Reid et al., 2002) or 3D encoding regions (Callahan
t al., 2002), two conventional RT PCRs (Reid et al., 2000; Rodriguez
t al., 1994), an RT linear-after-the exponential PCR (Pierce et al.,
010; Reid et al., 2010) and two RT-LAMP assays (Dukes et al.,
006; Shao et al., 2010). These CPMV particles are safe, since they
ig. 6. Use of RT-LAMP to detect the FMDV surrogate RNA encapsidated in the recombina
ssays  (Dukes et al., 2006: [dashed line] and Shao et al., 2010 [continuous line]) using a CP
id  not generate an ampliﬁcation signal (corresponding curves shown at the bottom of
amples by agarose-gel electrophoresis is shown for the two  RT-LAMP assays.he RT-qPCR targeting FMDV 3D. Points shown represent mean CT ± SD of triplicate
gative bovine epithelium suspension.
do not contain coherent sequences that can revert to infectious
FMD  virus. Furthermore, the recombinant CPMV used to generate
the particles was  engineered so that it is unable to move from cell
to cell and is thus unable to cause a productive infection of the
plants. This was achieved by generating an in-frame deletion within
the 48K region of RNA-2-encoded polyprotein. Such a deletion has
previously been shown to allow particle formation in individual
plant cells but to abolish the ability of the virus to cause a produc-
tive infection in whole plants (Wellink and van Kammen, 1989).
The deletion reduced the yield of particles produced in inoculated
leaves to approximately 1% of the yield obtained with the wild
nt CPMV particles. Real-time ampliﬁcation curves (A) are shown for two RT-LAMP
MV RNA positive sample. Results for negative bovine epithelial suspension sample
 the ﬁgure). [B] Post-ampliﬁcation analysis of these positive (+) and negative (−)
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ig. 7. Stability of the recombinant CPMV particles at room temperature (range 20–
etermined using the FMDV 3D RT-qPCR assay.
ype virus. However, this lower yield still gives sufﬁcient particles
or millions of PCR-based diagnostic reactions. Thus, this system
epresents a bio-safe option with no risk of accidentally spreading
MDV in the environment. Alternative approaches used to gener-
te encapsidated or armoured RNA exploit MS2  bacteriophage coat
rotein which provides a protective shell for the RNA, enabling stor-
ge at 4 ◦C for 60 days (Pasloske et al., 1998). These recombinant
PMV-like particles offer a more robust protection for the RNA and
ts surrounding environment since the CPMV-based particles can
urvive for a period of 46 days at 37 ◦C without any loss of the RNA
hen detected using RT-qPCR (Fig. 7). Furthermore, CPMV parti-
les can survive at 60 ◦C for at least one hour, across the range of
H 4–9 (Montague et al., 2011). Therefore, our surrogate FMDV RNA
ackaged in the CPMV particle could easily be shipped at room tem-
erature and could also be used in countries where maintaining the
old chain could be a challenge.
In addition to their use as standards and positive controls in
ational Reference Laboratories (NRL’s), these recombinant CPMV
articles have wider applications in other diagnostic scenarios. In
articular, they can be used to prepare biosafe surrogate spiked
aterials that could be used to evaluate molecular diagnostic
ssays and kits outside of government high-containment facili-
ies, and as positive controls for devolved or pen-side tests that
re now under development for FMDV detection in disease-free
nd endemic settings (Madi et al., 2012; King et al., 2008). Further-
ore, although this study has focussed on FMDV, this is a generic
pproach that can be easily applied to many other RNA viruses that
nfect animals, plants and man.
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